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The nucleoprotein (NP) of influenza A virus is the dominant antigen recognized by influenza virus-specific
cytotoxic T lymphocytes (CTLs), and adoptive transfer of NP-specific CTLs protects mice from influenza A
virus infection. BALB/c mouse cells (H-2") recognize a single A"-restricted CTL epitope of NP consisting of
amino acids 147 to 155. In the present study, mice were immunized with various vaccinia virus recombinant
viruses to examine the effect of the induction of primary pulmonary CTLs on resistance to challenge with
influenza A/Puerto Rico/8/34 virus. The minigene ESNP(147-155)-VAC construct, composed of a signal
sequence from the adenovirus E3/19K glycoprotein (designated ES) and expressing the 9-amino-acid NP
natural determinant (amino acids 147 to 155) preceded by an alanine residue, a similar minigene NP(Met
147-155)-VAC lacking ES, and a full-length NP-VAC recombinant of influenza virus were analyzed. The two
minigene NP-VAC recombinants induced a greater primary pulmonary CTL response than the full-length
NP-VAC recombinant. However, NP-specific CTLs induced by immunization with ESNP(147-155)-VAC did not
decrease peak virus titer or accelerate clearance of virus in the lungs of mice challenged intranasally with
A/PR/8/34. Furthermore, NP-specific CTLs induced by immunization did not protect mice challenged
intranasally with a lethal dose of A/PR/8/34. Sequence analysis of the NP CTL epitope of AIPR/8/34 challenge
virus obtained from lungs after 8 days of replication in ESNP(147-155)-VAC-immunized mice showed identity
with that of the input virus, demonstrating that an escape mutant had not emerged during replication in vivo.
Thus, in contrast to adoptively transferred CTLs, pulmonary NP-specific CTLs induced by recombinant
vaccinia virus immunization do not have protective in vivo antiviral activity against influenza virus infection.
Cytotoxic T lymphocytes (CTLs) appear to play an impor-
tant role in host immune response, limiting replication and
accelerating clearance of many different viruses. With respira-
tory viruses such as influenza A virus, adoptive transfer of
murine primary or restimulated immune spleen cells causes a
significant reduction of infectious virus levels in the lungs of
mice and prevents death from intranasal (i.n.) challenge with a
lethal dose of influenza A virus (1, 42). The specific effector-
cell subset was found to be the CD8+ major histocompatibility
complex class I-restricted antiviral CTLs, and the nucleopro-
tein (NP) was identified as the dominant viral determinant
recognized by these influenza virus-specific (38) and influenza
virus subtype-cross-reactive CTLs (9, 43). Since NP is con-
served among different strains of influenza A virus, it has been
suggested that an NP-based vaccine may protect against dif-
ferent influenza A virus subtypes (13). Indeed, adoptive trans-
fer of NP-specific CTL clones confers cross-protection from
lethal challenge with heterologous influenza A viruses (36).
CTLs specific for NS1 and hemagglutinin (HA) epitopes also
have protective effects when adoptively transferred to mice
(20, 21). In previous experiments in which protection was
observed, polyclonal or clonal CD8+-activated CTLs derived
from spleens of immunized mice were expanded in vitro by
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restimulation with antigen and were then transferred intrave-
nously to naive mice, often simultaneously with recombinant
interleukin-2 (24, 25, 36, 41). A positive correlation of CTL
cytolytic activity in vitro with the clearance rate of virus in the
lungs of influenza virus-infected mice has been observed (26).
However, studies in which immunization in vivo was used to
induce CTL activity have generally resulted in poor protective
immunity (5, 6, 14, 35) even after hyperimmunization of
animals (2, 4, 13, 40). Therefore, CTLs naturally induced by
infection in vivo, in contrast to results from adoptive transfer
experiments, appear to be less effective in their antiviral
function in vivo, and this was thought to be due to factors such
as insufficient activation and poor recruitment of effector cells
to the site of the virus infection.
CD8+ T cells recognize a peptide in association with major
histocompatibility complex class I molecules through the T-cell
receptor (37), and such peptides may be derived from two
different pathways of protein processing. In the major pathway,
transporter proteins convey peptides produced in the cytosol
into the endoplasmic reticulum (28). Alternatively, NH2-ter-
minal signal leader sequences adjacent to CTL epitopes can
bypass transporter proteins, presumably by posttranslational
transit through the protein-conducting channel, normally used
for signal recognition particle-mediated export. Once inside
the endoplasmic reticulum, signal peptidase presumably liber-
ates the peptide from the leader (17). The recent availability of
immunogenic signal sequence-CTL epitope constructs ex-
pressed by vaccinia virus vectors (3) provides an excellent
3505
3506 LAWSON ET AL.
opportunity to further examine the role of CTLs induced by
immunization in the resolution of influenza A virus infection.
Importantly, such studies can examine the contribution of
CD8+ CTLs in the absence of contributions of T-helper cells
and antiviral antibodies specific for influenza A virus.
Several murine major histocompatibility complex class I-re-
stricted CTL epitopes of NP from influenza A virus have been
characterized, including a Kd-restricted epitope, amino acids
(aa) 147 to 155 derived from A/Puerto Rico/8/34 virus. In
the present study, we used a vaccinia virus recombinant,
ESNP(147-155)-VAC, composed of a leader sequence from
the adenovirus E3/19K glycoprotein (designated ES) and the
NP minigene expressing the 9 aa 147 to 155 of NP preceded by
an alanine and a similar construct lacking the ES signal
sequence. We determined the ability of these viruses to induce
primary pulmonary NP-specific CTLs in BALB/c mice, and we
examined the role of such CTLs in the resolution of a
respiratory influenza virus infection. We unexpectedly found
that the primary pulmonary NP(147-155) peptide-specific
CTLs present in the lungs of vaccinia virus recombinant-
immunized mice lacked a biological effector function in the
clearance of influenza A/PR/8/34 virus infection from the lungs
and in the enhancement of survival of mice to a lethal
challenge of influenza A/PR/8/34 virus in vivo.
MATERIALS AND METHODS
Mice. Female BALB/c (H-2d) mice 6 to 10 weeks old were
obtained from Jackson Laboratories, Bar Harbor, Maine, and
Charles River Laboratories, Raleigh, N.C.
Viruses. The following vaccinia virus recombinants were
used: HA-VAC, expressing the full-length HA sequence of
A/PR/8/34 (H1N1); NP-VAC, expressing the full-length 495-
residue NP of A/PR/8/34; minigene NP(147-155)-VAC (12),
expressing a naturally processed peptide of NP (aa 147 to 155;
MIYORTRALV); minigene ESNP(147-155)-VAC (11), with
the ES leader sequence and expressing the NP peptide (aa 147
to 155) preceded by an alanine (MRYMILGLLALAAVC
SAATYORTRALV); minigene ESNvsv(52-59)-VAC, with
the ES leader sequence and expressing the N peptide of
vesicular stomatitis virus (aa 52 to 59). Recombinant vaccinia
viruses were grown in BSC-1 cells, sonicated before freezing at
-70°C, and titrated as described previously (10). Mouse-
adapted influenza virus A/PR/8/34 (H1N1) was grown in
10-day-old embryonated hen's eggs and, after 2 days at 37°C,
the infectious allantoic fluid was harvested and stored at
-70°C. Influenza virus was titrated in MDCK cells, and the
titers were expressed as 50% tissue culture infectious doses
(TCID50) per milliliter or per gram of lung tissue as described
previously (33).
Virus immunization and challenge. Mice were infected
simultaneously by the i.n and intraperitoneal (i.p) routes with
107 PFU in 100 ,lI (50 RI in each site) of vaccinia virus
recombinant after anesthesia with methoxyflurane (Pitman-
Moore Inc., Mundelein, N.J.). Anesthetized mice were chal-
lenged with either 102, 104-3, or 105 TCID50 of A/PR/8/34 virus
by the i.n. route on day 6 postinfection (PI). Mice administered
the vaccinia virus recombinants showed evidence of infection
by the presence of serum antibodies (titers of approximately
1:4,000 at day 28 PI) to vaccinia virus antigens by enzyme-
linked immunosorbent assay as previously described (15).
CTL assay. Target cells were prepared as described else-
where (43). Briefly, P815 (H-2d) cells, a DBA/2 mastocytoma
cell line, were pulsed with NP peptide (Met aa 147 to 155; 25
RI of 1 mg/ml), were infected with A/PR/8/34 or vaccinia virus,
or were left uninfected. Primary in vivo effector lymphocytes
were prepared from pooled lungs or spleens of vaccinia virus
recombinant-infected mice. Experiments used either lung ex-
udate lymphocytes from i.n. and i.p. inoculated mice or splenic
lymphocytes from intravenously (i.v.) inoculated mice. Cells
were washed in calcium- and magnesium-free Iscove's medium
and assayed the same day for cytotoxic activity in a standard
51Cr-release assay. Target cells were labeled with 100 pCi of
Na25tCrO4 for 1 h, washed and resuspended at 104 cells per
100 [lI. Effector cells were added in triplicate to targets at
various ratios, starting at 100:1. After 8 h at 37°C, the
supernatant was counted for 5"Cr release. The percent specific
cell lysis was 100 x ([experimental counts per minute {cpm} -
spontaneous cpm]/[total cpm - spontaneous cpm]).
Determination of virus titers in lungs. Virus titers are
expressed as mean log10 TCID50 ± standard error per gram of
lung homogenate (10%, wt/vol) prepared 4 days postchallenge.
Lung specimens from which virus was not recovered were
assigned a titer of 1.5, since the lowest limit of detectable virus
was 2.0 TCID5s/g.
Sequence analysis of NP CTL epitope. Influenza viral RNA
was extracted from A/PR/8/34 virus present in allantoic fluids
or lung homogenates of influenza virus-infected mice. Briefly,
the virus suspension was incubated with proteinase K (Boehr-
inger, Mannheim, West Germany) at 37°C for 10 min and
phenol-chloroform extracted, and the RNA was precipitated
with carrier yeast tRNA (Boehringer). Reverse transcription
was carried out with the influenza A virus NP-specific primer,
nucleotides 71 to 91 (5'-CTTACGAACAGATGGAGACTG
-3'), and reverse transcriptase (AMV, Life Sciences Inc., St.
Petersburg, Fla.). A 620-bp fragment of the synthesized NP
cDNA was amplified by PCR using the above primer and a
reverse NP primer, nucleotides 671 to 691 (5'-TTGY'ITf
TCGTCCATTCTCAC-3'). The PCR product was purified by
using spun columns, and the sequence across the CTL epitope
region was analyzed with the NP oligonucleotide, nucleotides
401 to 415 (5'-TCTGGCGCCAAGCTA-3') by Sequenase
version 2.0 (U.S. Biochemicals, Cleveland, Ohio) as described
previously (22).
RESULTS
Induction of primary pulmonary CTLs by immunization of
mice with vaccinia virus recombinants. Peak pulmonary CTL
activity to vaccinia virus and to expressed proteins occurs at
about day 6 PI (7). Mice infected with the influenza virus-
vaccinia virus recombinants were therefore assessed for pri-
mary pulmonary CTL activity at this time point. BALB/c mice
were inoculated with influenza virus A/PR/8/34-vaccinia virus
recombinants simultaneously by the i.n. and i.p. routes since
this immunization regimen induced CD8+ CTL-mediated re-
sistance to another respiratory virus, namely respiratory syn-
cytial virus (RSV) (19). A high dose of ESNP(147-155)-VAC
(107 PFU per mouse), but not 10-fold less (data not shown),
induced primary CTL activity against NP peptide (147-155)
and A/PR/8/34 virus as measured in the in vitro 5"Cr-release
assay (Fig. 1). The ESNP(147-155)-VAC and NP(Met 147-
155)-VAC induced a high level of primary pulmonary CTL
activity to NP peptide-pulsed targets (Fig. 1). Primary CTL
responses to A/PR/8/34, and to a lesser extent to NP peptide-
pulsed targets, were detected in mice infected i.n. with A/PR/
8/34 virus (Fig. 1, experiment 2). The other virus groups,
NP-VAC, HA-VAC, and ESNvsv-VAC, did not induce sig-
nificant CTL activity against NP peptide or A/PR/8/34 virus. As
expected, each group of mice given a vaccinia virus recombi-
nant exhibited primary CTL activity against vaccinia virus
antigens. These cytotoxic activities of lymphocytes obtained
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FIG. 1. Cytotoxic activity of primary pulmonary CTLs. BALB/c mice (H-2") were inoculated by the i.n. and i.p. routes with 107 PFU of
NP-VAC, ESNP(147-155)-VAC, NP(147-155)-VAC, HA-VAC, or ESNvsv(52-59)-VAC recombinant viruses or i.n. with 1037 TCID50 of
A/PR/8/34 virus. The titles above the graphs indicate viruses used to infect the mice. On day 6 PI, primary cytotoxic activity of pooled lung exudate
lymphocytes from 5 mice was evaluated by using 51Cr-labeled A/PR/8/34 virus-infected (0), vaccinia virus-infected (0), NP(Met 147-155)
peptide-pulsed (A), or uninfected (A) P815 (H-2") targets at the specific effector/target ratios. The top and bottom panels represent two separate
experiments.
from the lung exudates of mice which were administered
vaccinia virus recombinant viruses 6 days earlier were repro-
duced in four separate experiments (some data not shown) and
confirm our findings of primary splenic CTL activity induced
by standard i.v. immunization with ESNP(147-155)-VAC (Fig.
2). Thus, primary CTL responses to NP are induced by immu-
nization of mice with the NP minigene constructs, ESNP(147-
155)-VAC and NP(147-155)-VAC virus.
NP-specific CTLs induced by immunization do not reduce
peak influenza virus challenge titers or accelerate clearance of
virus in lungs of mice. Mice were inoculated i.n. and i.p. with
vaccinia virus recombinants as described above and challenged
i.n. with a low dose (102 TCID50) of A/PR/8/34 virus 6 days
later, and the amount of virus replication in the lungs was
quantitated 4 days postchallenge (Table 1). This time of
challenge was chosen since prior studies with the M2Rsv-VAC
virus demonstrated CTL activity and resistance to RSV chal-
lenge to be highest at this time point (19). Vaccination with
either the full-length NP-VAC, minigene ESNP(147-155)-
VAC or minigene NP(147-155)-VAC did not induce resistance
to A/PR/8/34 challenge virus replication in the lungs (Table 1).
Nonetheless, HA-VAC, as previously found for C57BL/6 and
other congenic mouse strains (14), induced resistance to
replication of challenge virus (reduction of 105). As expected,
the control ESNvsv(52-59)-VAC virus did not mediate resis-
tance to influenza A virus infection. We saw gross pulmonary
pathology from all groups except the HA-VAC-immunized
animals. These findings indicate that there is little to no
reduction of influenza virus replication in vivo by minigene
ESNP(147-155)-VAC or NP(147-155)-VAC vaccination of
mice despite induction of CTL responses to NP.
We next studied whether immunization with minigene NP-
vaccinia virus recombinant virus would accelerate the clear-
ance of the influenza challenge virus from the lungs. BALB/c
mice were immunized with the vaccinia virus recombinants and
challenged i.n. with A/PR/8/34 on day 6 as described above,
and the kinetics of virus replication in the lungs was deter-
mined from day 4 to day 10 postchallenge (Fig. 3). Virus was
not detected in the lungs taken at days 4, 6, 8, and 10
postchallenge of HA-VAC-immunized mice. However, virus
reached similar levels in the lungs of mice immunized with
ESNP(147-155)-VAC or control ESNvsv(52-59)-VAC at days
4 and 6 postchallenge. A difference in the clearance rate
between these two groups was not observed, and virus was no
longer detectable 10 days postchallenge. Therefore, NP-spe-
cific CTLs induced by immunization do not accelerate virus
clearance from the lungs.
NP-specific CTLs induced by immunization do not enhance
survival of mice challenged with a lethal dose of influenza virus. We
next examined whether the minigene NP-VAC vaccines could pro-
tect BALB/c mice from a challenge with a lethal dose of A/PR/8/34.
We compared the protective efficacies of immunization (i.n. and i.p.)
with ESNP(147-155)-VAC, NP(147-155)-VAC, NP-VAC, HA-
VAC, and ESNvsv(52-59)-VAC (Fig. 4). Six days after immumza-
tion, A/PR/8/34 virus was given i.n. at a dose of 1i0 TCID50, (which
represents approximately 1 50% lethal dose (Fig. 4A and B) or 105
Co
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FIG. 2. Cytotoxic activity of primary CTLs from BALB/c mice
primed with ESNP(147-155)-VAC. Mice were inoculated by the i.v.
route with 106.7 PFU (A) or by the i.n. and i.p. routes with 1070 PFU
(B) of recombinant vaccinia virus. On day 6 PI, primary cytotoxic
activities of pooled splenic (A) or lung exudate (B) lymphocytes were
evaluated by using 51Cr-labeled A/PR/8/34 virus-infected (0), vaccinia
virus-infected (0), NP(Met 147-155) peptide-pulsed (A), or unin-
fected (A) P815 targets at the specified effector/target ratios.
TCID50 (Fig. 4C and D), and the mice were observed daily over the
following 2 weeks for mortality. Immunization with HA-VAC com-
pletely protected mice from influenza virus, with 100% survival. In all
experiments, the survival rate of mice immunized with NP-VAC or
NP(147-155)-VAC was similar to that of the control group,
ESNvsv(52-59)-VAC. Surprisingly, mice immunized with ESNP
(147-155)-VAC had a lower survival rate than the control virus
group ESNvsv(52-59)-VAC following challenge with the lower
virus dose (1lW3 TCID90). High mortality rates were evident in the
groups immunized with ESNP(147-155)-VAC, NP(147-155)-VAC,
ESNvsv(52-59)-VAC, or NP-VAC and challenged with 1(0 TCID5o
of A/PR/8/34 virus. These studies show that although ESNP(147-
155)-VAC and NP(147-155)-VAC induce strong CTL responses to
NP peptide and A/PR/8/34 as measured in vitro, they do not protect
against a lethal course of respiratory disease in vivo and may possibly
contribute to immunopathology.
Analysis of the NP epitope. To assess whether the K"-
TABLE 1. Effect of vaccinia virus recombinant infection
on resistance to replication of challenge influenza
A/PR/8/34 virus in the lungs of BALB/c mice
Vaccinia recombinant No. of No. of Lung virus Loglo-
virus' expts mice" titer' (logl0 foldTCID50/g) reductiond
HA-VAC 2 11 .1.5 + 0.0 5.3
NP-VAC 2 11 6.0 + 0.2 0.8
NP(Met 147-155)-VAC 1 5 6.9 ± 0.1 0.0
ESNP(147-155)-VAC 3 25 6.8 + 0.1 0.0
ESNvsv(52-59)-VAC 3 15 6.8 + 0.2 NA'
a BALB/c mice received 107 PFU of each vaccinia virus-influenza virus
recombinant i.n. and i.p. on day 0. Mice were challenged i.n. on day 6 PI with 102
TCID50, of influenza A/PR/8/34, and lungs were removed 4 days later for
quantitation of virus.
^ Total number of mice in group.
cMean log1( virus titer ± standard error (TCID50/g of lung tissue) of total
number of animals for specified group. The lowest level of detectable virus was
2.0 TCID511g of lung tissue; undetectable virus was assigned a value of 1.5
TCID50/g.
dReduction in virus replication was determined by subtracting the mean log10
titer of influenza virus-vaccinia virus recombinant-primed animals from that of
mice primed with the control ESNvsv(52-59)-VAC virus.
" NA, not applicable.
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FIG. 3. Kinetics of virus clearance in lungs of immunized mice after
respiratory challenge with influenza A/PR/8/34 virus. Groups of three
to five BALB/c mice received 107 PFU of HA-VAC, ESNP(147-155)-
VAC, and ESNvsv(52-59)-VAC by the i.n. and i.p. routes and were
challenged i.n. on day 6 PI with 102 TCID50 of influenza A/PR/8/34
virus. Lungs were removed 4, 6, 8, and 10 days later for quantitation of
virus. Mean logl0 virus titers (TCID501) + standard error per gram of
lung tissue are shown. The limit of detectable virus was 2.0 TCID51/g
of lung.
restricted NP CTL epitope present in the A/PR/8/34 challenge
virus had undergone mutation during in vivo replication in
ESNP(147-155)-VAC-immunized animals, we sequenced the
region of NP cDNA derived from viral RNA (encoding the NP
peptide epitope) of influenza A virus obtained from lung
homogenates of challenged mice. Mice were infected with
ESNP(147-155)-VAC and challenged i.n. with A/PR/8/34 virus
on day 6 PI. Virus present in the lungs harvested after 8 days
of replication of challenge virus (day 14 after immunization)
was selected for nucleotide sequence analysis. The nucleotide
sequences of the NP CTL epitope region of parental and
recovered virus were identical, nucleotides 484 to 513 (cDNA,
5'-ACTTATCAGAGGACAAGAGCTCTTGTT). Thus, fail-
ure of the effector function of CTL in vivo does not reflect the
emergence of A/PR/8/34 escape mutants expressing an altered
CTL epitope.
DISCUSSION
In previous studies, we and others have found that one or
two doses of NP-VAC did not significantly decrease the
replication of A/PR/8/34 virus in the lungs of mice of several
major histocompatibility complex haplotypes, including H-2*,
H-2k, and H-2d (5, 6, 14, 35). In the present study, it was found
that a single immunization of BALB/c (H-2") mice with
full-length NP-VAC (105-3 or 107 PFU) did not induce primary
pulmonary NP CTL activity, and this lack of induction of
antiviral effector cells was thought to be largely responsible for
the observed lack of protection of NP-VAC against influenza
A virus infection. It was therefore exciting to find that mini-
gene ESNP(147-155)-VAC and NP(Met 147-155)-VAC, vac-
cinia virus recombinants expressing the H-2 Kd-restricted NP
CTL epitope (aa 147 to 155), induced primary pulmonary CTL
activity against NP in BALB/c mice 6 days after immunization.
However, mice with primary pulmonary NP-CTL activity were
not resistant to influenza virus respiratory infection in vivo.
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FIG. 4. Survival of vaccinated mice after respiratory challenge with
influenza A/PR/8/34 virus. Groups of five to nine BALB/c mice were
immunized with 107 PFU of HA-VAC, NP-VAC, NP(Met 147-155)-
VAC, ESNP(147-155)-VAC, or ESNvsv(52-59)-VAC, as specified, by
the i.n. and i.p. routes and were challenged i.n. on day 6 PI with 104-3
(A and B) and 105 (C and D) TCID50 of A/PR/8/34 virus in four
separate experiments. Mice were observed for mortality over 14 days
postchallenge.
This finding was surprising to us, since primary pulmonary
CTL effectors induced by immunization with M2RsV-VAC
readily decreased replication of RSV challenge virus adminis-
tered 6 days after immunization (19). Although protection
against RSV was short-lived, resistance correlated with the
level of primary pulmonary CTL activity mediated by CD8+ T
cells (19). Differences in the virulence levels of these viruses
could contribute to the observed differences in efficacy, since
RSV infection is only semipermissive in mice, while influenza
A/PR/8/34 virus infection can be lethal.
CTL activity induced by immunization with vaccinia virus
recombinants can induce resistance to certain virus infections.
The immediate-early nonstructural antigen, pp89, of murine
cytomegalovirus expressed by vaccinia virus recombinant in-
duces CD8+ CTLs which protect mice from lethal murine
cytomegalovirus disease (8, 18). A spectrum of CTL activities
to NP of lymphocytic choriomeningitis virus (LCMV) and
protective efficacies has been observed in NPLCMV-VAC-
infected mouse strains (16). NP-CTL activity was not detected
in B10.BR (H-2k) mice, a low and transient NP-CTL activity
associated with partial resistance was seen in B10.D2 (H-2")
mice, and a high and longer-lasting NP-CTL activity associated
with strong resistance in C57BL/6 (H-2b) mice was found.
Importantly, minigenes of CTL epitopes of LCMV NP and
glycoprotein GP coexpressed by vaccinia virus can induce a
protective CTL response in certain mouse strains (31, 32).
These findings with minigene-vaccinia virus recombinants sug-
gest that CTLs, in the absence of other immunological effec-
tors such as CD4+ T cells or antibodies, by themselves are
capable of mediating resistance to certain viruses. Thus, there
are several examples of the effectiveness of vaccinia virus-
based immunogens in which CD8+ CTLs induced by immuni-
zation provide protection.
Recently, intramuscular injection of full-length naked cDNA
for NP of influenza virus expressed by a mammalian plasmid
vector has been reported to protect mice against lethal influ-
enza virus infection (39). Following the inoculation of NP-
cDNA into skeletal muscle cells of mice, both CTLs and
antibodies to NP antigens are induced. Partial resistance to
both homologous and heterosubtypic influenza A virus chal-
lenge was observed, but the mediators of the resistance were
not defined. Clearly, both CD4+ and CD8+ T cells were
induced, and are possible mediators of the observed protec-
tion. Perhaps, prolonged presence of NP antigen in transfected
muscle cells induces an immune response qualitatively differ-
ent from that induced by vaccinia recombinant virus-infected
cells, and this could be an explanation for the differences in
efficacy of NP-cDNA versus NP-VAC.
In contrast to the findings from our present study, adoptive
transfer of murine influenza virus-specific CTLs has provided
levels of protection ranging from 0.7 to 4.0 loglo reduction of
virus titers in lungs determined at day 4 to 6 postchallenge
associated with 50 to 100% survival from lethal influenza virus
challenge (see the introduction). Experiments using a variety
of inbred mouse strains (CBA, BALB/c, and CB6F1), virus
strains (A/WSN, A/PR18/34, A/Jap/57, A/X-31, AIUSSR/90/77,
and A/PC), and protocols for in vitro restimulation of CTLs
were performed. In the vast majority of these studies, poly-
clonal or clonal CTLs derived from spleen or lungs of immu-
nized mice have been used for adoptive transfer. Numbers of
cells ranging from approximately 106 to 108 have been trans-
ferred by the i.v. route with or without simultaneous injection
of recombinant interleukin-2. Memory CD8+ T cells were
found more efficient at virus clearance than memory CD4+ T
cells (23), and a positive correlation between the restimulation
of such CTLs in vitro and the reduction of influenza virus in
lungs of mice was observed.
Several immunological mechanisms could underlie the
seemingly contradictive evidence of the protective effects of
influenza virus-specific CTLs generated in vivo and of those
restimulated in vitro. First, the number of NP-specific CTLs
stimulated in vivo by immunization and present at the tissue
site of challenge virus replication may not be sufficient to
restrict virus replication, whereas larger numbers of adoptively
transferred CTLs would traffic to the lung and accumulate in
the lung parenchyma, bronchial mucosa, epithelium, and air-
way lumen (27). We have found a total of approximately 107
lymphocytes present in the lungs of ESNP(147-155)-VAC-
infected BALB/c mice at day 6 PI, and of this population only
a fraction will be CMLs specific for NP. In cell transfer
experiments, larger numbers of NP-specific T cells are trans-
ferred (up to 108 cells). The minimum number of adoptively
transferred primary immune T cells (5 x 107) was found to be
higher than that for secondary polyclonal T cells (2 x 107) for
a 100% survival rate of CBA mice to challenge influenza
A/WSN virus infection (41). Second, the inherent in vivo
antiviral activities of CTL populations may differ depending on
whether the CTLs are restimulated in vitro. For example, it is
possible that CD8+ T cells with high densities and/or affinities
of the T-cell receptors specific for the NP epitope might be
selectively amplified during in vitro restimulation. Such CTLs
may have stronger in vivo antiviral activities than CTLs in-
duced by a single immunization of NP in vivo. Third, since the
avidities of the T-cell receptors for NP can be affected by
accessory and/or adhesion molecular interactions (34), it is
possible that CTLs induced by in vitro restimulation have a
lower energy threshold for activation than primary CTLs
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induced by immunization and therefore might be active earlier
during a virus infection in vivo. Fourth, it is possible that in
vitro restimulation of CTLs optimizes the secretion of antiviral
molecules such as gamma interferon or the degranulation of
the CTL, resulting in the release of lethal perforins during
interaction with virus-infected cells. Fifth, the presence of
T-helper cells specific for influenza virus may augment resis-
tance mediated by CTLs that are induced by immunization in
vivo. Such T-helper cells would likely not be induced by
NP-vaccinia virus minigene recombinants bearing only the
CTL epitope. Exogenous helper factors present as lymphokine
supplements in the populations of CTLs restimulated in vitro
may alleviate the need for T-helper cells in the adoptive
transfer experiments (30). Sixth, since CTLs clearly differ in
their protective activities in vivo depending on the epitope
recognized (16), it is possible that the NP epitope (aa 147 to
155) was one capable of only a very weak in vivo effect.
Polyclonal nonrestimulated splenic-influenza-virus-immune T
cells adoptively transferred to mice have been reported to
induce resistance to challenge influenza virus infection (41,
42). However, the mediators of this protection are undefined
and may include multiple effector T-cell (CD8+ and/or CD4+)
clones. Exhaustion of antiviral CTLs possibly by anergy or
apoptosis has been demonstrated for persistent viral infections
such as LCMV (29). It is unknown whether the diminished
NP-specific CTL protective immunity seen in our influenza
virus-challenged mice is due to exhaustion of CTLs driven by
NP antigen, but this remains a possibility. However, we think
this is unlikely to be a major factor, since a low dose of
challenge virus was used in the present study and exhaustion
with LCMV required high doses of virus. Importantly, the
present study in which the in vitro cytotoxic activity and in vivo
efficacy of CD8+ CTLs have been found to be dissociated
provides a system in which the mediators of antiviral resistance
in vivo can be further defined.
The potential usefulness of the inclusion of CTL epitopes in
vaccines for respiratory virus infections such as influenza A
virus has been examined in the present study. Our findings, in
the context of those of others (40), emphasize the importance
of a complete analysis of the immunogenicity and protective
efficacy of a CTL epitope before its inclusion in a vaccine is
validated. First, the proposed CTL epitope or set of CTL
epitopes must be recognized by a high percentage of the target
human population. Second, the immunogenicity of the CTL
epitope in the vaccinees should be readily measurable by in
vitro assays. Third, and most importantly, the CTL response
induced by immunization with the virus vaccine must ade-
quately protect the host from disease caused by the wild-type
virus and this protection should be long lasting. Clearly, the
present study demonstrates that the presence of in vitro
cytotoxic activity in vaccinated animals is insufficient to predict
in vivo efficacy of the vaccine for influenza virus and this
underscores the need for the efficacy studies in vivo. Further-
more, the NP-specific CTL epitope examined in the present
study, or another CTL epitope with comparable in vivo prop-
erties, would not appear to be a useful component of an
influenza A virus vaccine.
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